Advanced Filters
noise

Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 534 clinical trials
A Andrew Branagan, MD, PhD

Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: Arm 1: Selinexor + dexamethasone + pomalidomide …

18 years of age All Phase 1/2
D Dickran Kazandjian, MD

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.

18 years of age All Phase 2
U Urvi A Shah, MD, MS

A Dietary Study for People With Multiple Myeloma

The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). The researchers will measure quality of life by having …

18 years of age All Phase N/A
Y Yichu Nie, Doctor

JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory multiple myeloma. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY232 injection in the treatment of relapsed/refractory multiple myeloma.

18 - 75 years of age All Phase 0
L Luciano Costa, MD

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow. For patients who become MRD …

18 years of age All Phase 2

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

18 years of age All Phase 2
M Margaret McNeely, PhD

Prehab Prior to Stem Cell Transplantation in Multiple Myeloma

The primary purpose of this study is to see if individuals with Multiple Myeloma are able and interested in taking part in a tailored exercise program while undergoing their chemotherapy prior to a stem cell transplant. We also hope to learn if this type of program, along with a flexible …

18 years of age All Phase N/A
F Fang Liu, MD/PhD

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.

years of age All Phase 1
D David Gomez-Almaguer, MD

Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients

This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.

18 years of age All Phase 2
G Gang An

BCMA CAR-T for Dynamic High-risk Multiple Myeloma

This is a single-arm, open-label study to evaluate the efficacy and safety of BCMA CAR-T in dynamic high-risk patients with multiple myeloma

18 - 75 years of age All Phase 2

Simplify language using AI